Celltrion Launches STEQEYMA® (Ustekinumab-stba) in the U.S. Following FDA Approval, Offering a Cost-Effective Biosimilar Alternative to STELARA®

Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U....

March 13, 2025 | Thursday | News
Centivax Partners with Emery Pharma to Advance Potency Testing for Pan-Influenza Vaccine

Centivax, a biotechnology company that develops broad-spectrum vaccines to combat rapidly evolving pathogens, has announced a strategic collaboration with ...

March 12, 2025 | Wednesday | News
Gilead Presents Promising Phase 1 Data for Once-Yearly Lenacapavir as HIV Pre-Exposure Prophylaxis

Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...

March 12, 2025 | Wednesday | News
Merck ( MSD ) Opens $1 Billion Vaccine Manufacturing Facility in Durham, North Carolina

Merck, known as MSD outside of the United States and Canada, announced  the opening of a new, $1 billion, 225,000-square-foot facility dedicated to va...

March 12, 2025 | Wednesday | News
SK bioscience Secures PAHO Contract Extension to Supply SKYVaricella® to Latin America Through 2027

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the compan...

February 28, 2025 | Friday | News
Avance Biosciences Earns CLIA Registration to Enhance Clinical Trial Support

Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that i...

February 27, 2025 | Thursday | News
EMA Approves New 2 mL Pre-Filled Pen Option for TAKHZYRO® to Treat Hereditary Angioedema in Adolescents and Adults

Takeda announced that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in...

February 25, 2025 | Tuesday | News
Regeneron Reports Promising Results from Phase 1/2 CHORD Trial of Investigational Gene Therapy DB-OTO for Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have p...

February 25, 2025 | Tuesday | News
Innovent Biologics’ Ipilimumab Injection Receives NDA Acceptance and Priority Review for MSI-H/dMMR Colon Cancer in China

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment o...

February 24, 2025 | Monday | News
Merilog Receives FDA Approval as the First Rapid-Acting Insulin Biosimilar

The U.S. Food and Drug Administration (FDA) approved Merilog (insulin aspart szij) as a Novolog biosimilar to (insulin aspart) to improve glycemi...

February 20, 2025 | Thursday | News
Zoetis Receives USDA Conditional License for Avian Influenza Vaccine for Chickens

Zoetis announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its...

February 17, 2025 | Monday | News
GSK Receives FDA Approval for Penmenvy, a Pentavalent Meningococcal Vaccine for Adolescents and Young Adults

GSK plc announced that the US Food and Drug Administration (FDA) has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use i...

February 17, 2025 | Monday | News
Theratechnologies Resumes Distribution of EGRIFTA SV® Following FDA Approval to Release Manufactured Batches

Theratechnologies Inc., a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...

February 14, 2025 | Friday | News
Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails to Meet Efficacy Endpoints in Phase III E.mbrace Study

Interim analysis of data from the Phase III E.mbrace study (clinical trial identifier: NCT04899336), conducted by an independent data monitoring committee,...

February 13, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close